<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>15(1)</volume><submitter>Berlinger MS</submitter><pubmed_abstract>Sepsis, a condition characterized by immune dysregulation, is the leading cause of in-hospital mortality and requires rapid treatment. Assessing immune dysregulation has been challenging. The IntelliSep Index (ISI), a novel biomarker which leverages microfluidic deformability cytometry to assess immune activation, has been evaluated as a test for Emergency Department use but it is unclear how the signal evolves as patient condition evolves. In a 47-patient cohort with hospital stays ≤ 14 days, ISI provided a good indicator of disease progression by blinded physician review. ISI trends correlated with clinical improvement over time. During the first 12 h following presentation, ISI was unaffected by antibiotic treatment initiated in the emergency department (ED). After this period however, </pubmed_abstract><journal>Scientific reports</journal><pagination>30501</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12368155</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Temporal trends of a cellular host response test for sepsis and a comparison with selected biomarkers of inflammation and infection.</pubmed_title><pmcid>PMC12368155</pmcid><pubmed_authors>Ochsner SP</pubmed_authors><pubmed_authors>O'Neal HR</pubmed_authors><pubmed_authors>Daigle J</pubmed_authors><pubmed_authors>Avornu G</pubmed_authors><pubmed_authors>Walker JE</pubmed_authors><pubmed_authors>Cembellin-Kao A</pubmed_authors><pubmed_authors>Maia Q</pubmed_authors><pubmed_authors>Sorrells M</pubmed_authors><pubmed_authors>Quiriarte H</pubmed_authors><pubmed_authors>Shah AM</pubmed_authors><pubmed_authors>Thomas CB</pubmed_authors><pubmed_authors>Berlinger MS</pubmed_authors><pubmed_authors>Rothman R</pubmed_authors><pubmed_authors>Sheybani R</pubmed_authors><pubmed_authors>Tse HTK</pubmed_authors><pubmed_authors>Jagneaux T</pubmed_authors><pubmed_authors>Scoggins R</pubmed_authors><pubmed_authors>King C</pubmed_authors><pubmed_authors>Fenstermacher K</pubmed_authors><pubmed_authors>Kurien EJ</pubmed_authors><pubmed_authors>Yonamine C</pubmed_authors><pubmed_authors>Spielmann G</pubmed_authors><pubmed_authors>Robertson D</pubmed_authors><pubmed_authors>Hager DN</pubmed_authors><pubmed_authors>Kim Y</pubmed_authors><pubmed_authors>Obrebski M</pubmed_authors></additional><is_claimable>false</is_claimable><name>Temporal trends of a cellular host response test for sepsis and a comparison with selected biomarkers of inflammation and infection.</name><description>Sepsis, a condition characterized by immune dysregulation, is the leading cause of in-hospital mortality and requires rapid treatment. Assessing immune dysregulation has been challenging. The IntelliSep Index (ISI), a novel biomarker which leverages microfluidic deformability cytometry to assess immune activation, has been evaluated as a test for Emergency Department use but it is unclear how the signal evolves as patient condition evolves. In a 47-patient cohort with hospital stays ≤ 14 days, ISI provided a good indicator of disease progression by blinded physician review. ISI trends correlated with clinical improvement over time. During the first 12 h following presentation, ISI was unaffected by antibiotic treatment initiated in the emergency department (ED). After this period however, </description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Aug</publication><modification>2026-05-05T19:02:23.789Z</modification><creation>2026-04-07T21:50:57.419Z</creation></dates><accession>S-EPMC12368155</accession><cross_references><pubmed>40836052</pubmed><doi>10.1038/s41598-025-14860-w</doi></cross_references></HashMap>